Is upregulation of BCL2 a determinant of tumor development driven by inactivation of CDH1/E-cadherin?

PLoS One · 2013 · PMC3758309 · PMID 24023670

Europe PMC DOI

hedged sentence

0.0640

closest p · 1.3× alpha

0.0640

boldest claim

The sentences

showed a trendP = 0.064so close (0.05 < p ≤ 0.1)

When compared with an appropriate control group, ILBCs showed a trend towards an increased frequency of BCL2-negative cases ( P = 0.064).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.